Antibiotic Now Available in Capsule Form

Published Online: Friday, June 28, 2013
Follow Pharmacy_Times:
This article is brought to you by Lupin Pharmaceuticals, Inc.
 
Suprax (cefixime) is now available in 400 mg capsules as well as 400 mg tablets and 100 mg/5 ml and 200 mg/5 ml suspensions. The capsule form of the cephalosporin antibiotic is designed to provide a dosage form preferred by most patients. In a survey of 1000 patents, more than half preferred capsules over tablets, and respondents associated capsules with safety and increased efficacy.
 
Suprax capsules can be taken once-daily, just like the 400 mg tablet form, and can be administered without food. However, neither the capsule nor the tablet form should be substituted for chewable tablets or suspension in treatment of otitis media in children. Suprax 400 mg capsules are available in a 10-pack and can be purchased using the $25 Suprax co-pay savings card. For details, go to www.supraxrx.com.
 
Suprax is indicated for treatment of otitis media caused by Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes; pharyngitis and tonsillitis caused by S pyogenes; acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and H influenzae; and uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis.
 

Related Articles
A drug therapy for epilepsy and shingles pain is being voluntarily recalled by its manufacturer due to complaints of empty capsules.
With a mission to help pharmacists throughout the world prevent the potential spread of the Ebola virus, the International Pharmaceutical Federation has launched a suite of resources to advise community pharmacists on the threat.
While the Ebola scare has started to fade away in the United States, the crisis continues to devastate West Africa, where the death toll has climbed above 5000 with more than 14000 confirmed and suspected cases.
Enhancing supportive care improves the chances of a patient surviving an Ebola infection.
Latest Issues
$auto_registration$